Liver Cancer in a Cirrhotic Liver: Why the Treatment Approach Is Completely Different

Table of Contents

• 1. Two Patients, Same Diagnosis, Completely Different Problems
• 2. Why Most Liver Cancer in India Grows in a Liver That Is Already Sick
• 3. The Real Reason the Surgeon Says “Inoperable”
• 4. Treating the Tumour Without Breaking the Liver: The IR Approach
• 5. RFA and Microwave Ablation: Burning the Tumour Through a Needle
• 6. TACE: Poisoning and Starving the Tumour at the Same Time
• 7. When You Need Both, and How They Work Together
• 8. What About Liver Transplant?
• 9. The Question Families Should Be Asking

1. Two Patients, Same Diagnosis, Completely Different Problems

Imagine two men sitting in a clinic. Both have just been told they have a 3-centimetre tumour in the liver. Both reports say Hepatocellular Carcinoma. HCC. Liver cancer.

Patient A has a healthy liver. No cirrhosis. No hepatitis history. His tumour was found incidentally on a routine scan. A surgeon can operate, cut out the segment of liver containing the tumour, and the remaining liver will regenerate. Recovery takes a few weeks. The liver heals. Problem solved.

Patient B has the same size tumour. But his liver is cirrhotic. Years of hepatitis B, or alcohol, or both, have scarred the organ. The liver is stiff, shrunken, struggling to do its basic job. His blood tests show low albumin, his platelets are down, and he has early signs of portal hypertension.

If a surgeon cuts out part of Patient B’s liver, the remaining liver may not cope. It does not have the reserve to regenerate. It cannot compensate for the lost tissue. Instead of saving him, the surgery could push him into liver failure.

Same tumour. Same size. Completely different problem. Because in Patient B, the enemy is not just the cancer. The enemy is the cancer plus the liver it is sitting in.

This is the reality that most families in India are never clearly told. When a doctor says “inoperable,” most people hear “untreatable.” Those are not the same thing. Not even close.

 

2. Why Most Liver Cancer in India Grows in a Liver That Is Already Sick

This is the part that makes India’s liver cancer story different from most Western countries.

In India, the overwhelming majority of HCC does not appear in a healthy liver. It develops on a background of chronic liver disease, almost always one of these:

• Hepatitis B. India has an estimated 40 million hepatitis B carriers. Many do not know they are infected until the damage is advanced. The virus causes chronic inflammation, which over decades leads to cirrhosis, and cirrhosis is the soil in which HCC grows.
• Hepatitis C. Less common than B in India but equally dangerous. Chronic hepatitis C silently scars the liver over 10 to 20 years. By the time HCC appears, the underlying liver is already compromised.
• Alcohol-related liver disease. Chronic heavy alcohol use leads to fatty liver, then alcoholic hepatitis, then cirrhosis. In many Indian men, the drinking has been going on for 15 or 20 years before anyone checks the liver seriously. By then, cirrhosis is established and HCC risk is high.
• Non-alcoholic fatty liver disease (NAFLD/NASH). The rising epidemic. Driven by obesity, diabetes, and sedentary lifestyles. NASH can progress to cirrhosis even without a drop of alcohol. This is increasingly being recognised as a growing cause of HCC in India.

The common thread is this: by the time the tumour is found, the liver has already been through years or decades of damage. It is not a healthy organ with a tumour in it. It is a sick organ with a tumour in it. And that distinction changes everything about how treatment has to be planned.

3. The Real Reason the Surgeon Says “Inoperable”

When a surgeon says a liver cancer is “inoperable,” families often assume it means the tumour is too big, or too advanced, or has spread everywhere. Sometimes that is true. But very often, especially in India, the reason is something different entirely.

The liver itself cannot handle the surgery.

A healthy liver is remarkably resilient. You can remove up to 70% of a healthy liver, and the remaining 30% will regenerate back to near-full size within weeks. Surgeons rely on this regenerative power every time they do a liver resection.

But a cirrhotic liver has lost that ability. The scar tissue that replaces healthy liver cells does not regenerate. It does not function. It just sits there, stiff and useless. If you remove a segment of a cirrhotic liver, the remaining portion may not have enough working cells to keep the patient alive. The result can be post-operative liver failure, which is often fatal.

This is why liver surgeons assess something called hepatic reserve before deciding whether to operate. They look at blood tests (albumin, bilirubin, INR, platelet count), they check for signs of portal hypertension (varices, ascites, splenomegaly), and they sometimes do specialised tests to measure how much functional capacity the liver still has.

When the reserve is too low, surgery becomes too dangerous. Not because the tumour cannot be reached. But because the liver cannot survive the operation.

And this is where the conversation often breaks down. The family hears “inoperable” and goes home believing nothing can be done. The surgeon may not mention alternatives because those alternatives belong to a different specialty. The patient falls through the gap.

But the gap does not have to exist. Because for exactly these patients, with exactly these sick livers, Interventional Radiology has an entire set of tools designed to treat the tumour while leaving the liver intact.

4. Treating the Tumour Without Breaking the Liver: The IR Approach

The fundamental principle of treating HCC in a cirrhotic liver is this: you cannot afford to lose any more liver tissue than absolutely necessary.

Surgery removes a chunk of liver. In a healthy organ, that chunk grows back. In a cirrhotic organ, it does not. So the ideal treatment for these patients is one that destroys the tumour while preserving every possible gram of functioning liver around it.

This is precisely what image-guided IR procedures are designed to do.

Instead of cutting out liver tissue, we destroy the tumour from the inside, either by burning it with a needle (ablation) or by blocking its blood supply and delivering chemotherapy directly into it (TACE). In both cases, the surrounding liver is spared. No tissue is removed. No regenerative capacity is demanded from an organ that has none to give.

For patients with cirrhosis, IR-based treatments are often not the “alternative.” They are the primary treatment. International guidelines (including the Barcelona Clinic Liver Cancer staging system, which is the most widely used framework for HCC treatment decisions) place ablation and TACE as first-line therapies for patients with early and intermediate stage HCC on a background of cirrhosis.

In other words, for these patients, the right treatment was never surgery in the first place. It was always IR.

5. RFA and Microwave Ablation: Burning the Tumour Through a Needle

We have written about how radiofrequency ablation (RFA) works in detail in a separate article. Here we will focus on why it matters specifically for cirrhotic patients.

In ablation, a thin needle is inserted through the skin into the tumour under ultrasound or CT guidance. Once positioned inside the tumour, the needle delivers intense, controlled heat (via radiofrequency energy or microwave energy) that literally cooks and kills the cancer cells. The dead tissue is gradually absorbed by the body over weeks.

Why this matters for cirrhotic livers:

• No liver tissue is removed. The tumour is destroyed in place. The liver does not need to regenerate anything. The surrounding healthy (or relatively healthy) tissue is preserved. The procedure is done through a skin puncture, not an abdominal incision, so the physical stress on the body is minimal. Most patients are eating and walking the same day or the next.
• Ablation works best for smaller tumours, typically under 3 to 4 centimetres. For early-stage HCC in a cirrhotic liver, ablation can be curative. Studies have shown survival rates comparable to surgical resection in well-selected patients, with significantly lower complication rates and virtually no risk of post-operative liver failure.

For patients with one or two small tumours and a liver that cannot tolerate surgery, ablation is often the single best treatment available.

6. TACE: Poisoning and Starving the Tumour at the Same Time

When the tumour is too large for ablation, or there are multiple tumours, or the tumour is in a location where a needle cannot safely reach it, a different IR tool comes into play: Trans-Arterial Chemo-Embolisation, or TACE.

The concept is elegant and aggressive at the same time.

Every tumour needs blood to survive. In the liver, tumours get most of their blood supply from the hepatic artery, while normal liver tissue gets most of its supply from the portal vein. This anatomical quirk is what makes TACE possible.

Through a catheter inserted via a puncture in the wrist or groin, Dr. Parul Garg navigates to the specific branch of the hepatic artery that feeds the tumour. Through that catheter, two things happen:

• Concentrated chemotherapy is delivered directly into the tumour. Because the drug goes straight to the cancer rather than circulating through the entire body, the dose at the tumour site is many times higher than what you would get with standard IV chemotherapy. Meanwhile, the rest of the body is largely spared from side effects. Less nausea. Less hair loss. Less immune suppression.
• The feeding artery is then blocked with tiny particles. This cuts off the tumour’s blood supply. Without blood, the tumour cannot get oxygen or nutrients. It begins to die. The normal liver tissue survives because it draws most of its blood from the portal vein, not the artery that was blocked.

Double attack. Poison and starve. The tumour gets hit from two directions in a single sitting.

TACE is particularly important in intermediate-stage HCC, where tumours are too large or too numerous for ablation but the cancer has not spread outside the liver. It is also used as a bridge therapy for patients on the waiting list for a liver transplant, keeping the tumour controlled while they wait for a donor.

For the cirrhotic patient specifically, TACE is valuable because it does not require any liver tissue to be cut or removed. The liver stays intact. The treatment is targeted. And it can be repeated if needed.

7. When You Need Both, and How They Work Together

In clinical practice, HCC in a cirrhotic liver rarely fits into a single neat category. Patients may have one small tumour that is perfect for ablation and another nodule that is better addressed with TACE. Or a tumour may be too large for ablation alone but can be downsized with TACE first, then finished off with ablation.

This combined approach is something IR specialists are uniquely positioned to deliver, because both tools belong to the same specialty. The same doctor who performs the TACE also performs the ablation. The treatment plan is unified, not split between two different teams who may not communicate well with each other.

At our clinic, Dr. Parul Garg evaluates each case with a combination of imaging (CT, MRI, sometimes contrast-enhanced ultrasound) and liver function assessment. The decision is never just about the tumour. It is always about the tumour in the context of the liver it lives in. A 3 cm tumour in a Child-Pugh A liver (relatively preserved function) may be treated differently from the same tumour in a Child-Pugh B liver (more advanced cirrhosis). The treatment is tailored to both problems simultaneously.

For a broader overview of how different stages of liver cancer are approached, you can read our stage-by-stage treatment guide.

8. What About Liver Transplant?

If the liver is cirrhotic and the tumour is there because the liver is sick, the logical question is: why not replace the whole liver?

Liver transplant is, in theory, the most complete solution for HCC in cirrhosis. It removes the tumour and the diseased liver in one stroke, replacing them with a healthy organ. For patients who meet the criteria (most commonly the Milan criteria: a single tumour up to 5 cm, or up to three tumours each 3 cm or less, with no vascular invasion and no spread outside the liver), transplant offers the best long-term outcomes.

But transplant has enormous practical barriers in India:

• Donor shortage. The gap between patients needing a liver and available organs is vast. Waiting times can stretch months or years. During that wait, the tumour does not pause. It keeps growing.
• Cost. Liver transplant in India costs anywhere from 20 to 35 lakh rupees or more, depending on the centre. For many families, this is simply not feasible.
• Medical fitness. Not every cirrhotic patient is healthy enough for transplant surgery. Advanced age, cardiac problems, severe portal hypertension, or other comorbidities can rule it out.

This is where IR procedures serve a critical bridging role. While a patient waits for a transplant, TACE and ablation can keep the tumour under control, preventing it from growing beyond transplant criteria. In some cases, IR treatment can even downstage a tumour (shrink it enough that a patient who was initially outside transplant criteria becomes eligible).

And for patients who will never be transplant candidates, either because of cost, donor availability, or medical fitness, IR-based treatments become the primary long-term management strategy. Not a bridge to something else. The main road.

9. The Question Families Should Be Asking

If someone in your family has been diagnosed with liver cancer and also has cirrhosis, hepatitis B, hepatitis C, or a history of heavy alcohol use, the most important question is not “Can the tumour be operated on?”

The most important question is: “What can be done for this tumour in this liver?”

Because the answer almost always exists. It may not be surgery. It may not be a transplant. But ablation, TACE, or a combination of both can treat the tumour, preserve the liver, and in many cases meaningfully extend life and improve its quality.

“Inoperable” does not mean “untreatable.” It means the surgical door is closed. But there are other doors. And they have been open for years.

If nobody has mentioned these options to you, it is probably because the conversation happened within a surgical specialty, and the referral to an interventional radiologist did not take place. That gap is closable with one phone call.

To discuss a liver cancer case with Dr. Parul Garg:

🌐 Book an Appointment

📞 Phone / WhatsApp: +91-9211978100

📧 Email: [email protected]

Share your CT or MRI scans, blood reports, and any previous opinions. We will give you a clear, honest assessment of what is possible.

A sick liver does not mean a hopeless situation. It means the approach has to be smarter, gentler, and more precise. That is exactly what Interventional Radiology is built for.